4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes
Background: Combination of insulin with oral antidiabetic drugs is a valid option, but oral combination therapy emerged as an alternative treatment in type 2 diabetes (T2DM). However, the effects on blood pressure (BP) and vascular function of such combination therapies is less clear. Methods: In t...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-02-01
|
| Series: | Artery Research |
| Online Access: | https://www.atlantis-press.com/article/125934393/view |
| _version_ | 1811301395036372992 |
|---|---|
| author | Christian Ott Susanne Jung Agnes Bosch Dennis Kannenkeril Kristina Striepe Roland Schmieder |
| author_facet | Christian Ott Susanne Jung Agnes Bosch Dennis Kannenkeril Kristina Striepe Roland Schmieder |
| author_sort | Christian Ott |
| collection | DOAJ |
| description | Background: Combination of insulin with oral antidiabetic drugs is a valid option, but oral combination therapy emerged as an alternative treatment in type 2 diabetes (T2DM). However, the effects on blood pressure (BP) and vascular function of such combination therapies is less clear.
Methods: In this study 101 patients with T2DM were randomized to receive either empagliflozin 10 mg and linagliptin 5 mg (E+L group) orally or metformin and insulin glargine (M+I group, with dose adjustments according to glucose levels), for 3 months. Patients underwent BP and vascular examination at baseline and after 12 weeks of treatment, including measurement of office and ambulatory BP and vascular function under clinical and ambulatory conditions by validated systems.
Results: In comparison to baseline, office, 24-hour ambulatory BP and central blood and pulse pressure (PP) values decreased significantly after 12 weeks of treatment with E+L, whereas there was no significant change in vascular parameters in the M+I group (Table 1). Comparing the 2 groups, there were significant decreases in 24-h ambulatory peripheral systolic (mean difference between the 2 groups: −5.2 ± 1.5 mmHg, p = 0.004), diastolic BP (−1.9 ± 1.0 mmHg, p = 0.036) and PP (−3.3 ± 1.0 mmHg, p = 0.007) in favour of E+L. Central systolic BP (−5.56 ± 1.9 mmHg, p = 0.009), forward pressure pulse height (−2.0 ± 0.9 mmHg, p = 0.028) and 24-h ambulatory central systolic (−3.6 ± 1.4 mmHg, p = 0.045), diastolic BP (−1.95 ± 1.1 mmHg, p = 0.041) and 24-h pulse wave velocity (−0.14 ± 0.05 m/s, p = 0.043) were reduced to a greater extent in the E+L group than in the M+I group.
Table 1
E + L
M + I
Baseline
12 weeks
p-value
Baseline
12 weeks
p-value
Peripheral (brachial) BP values
24-h ambulatory SBP [mmHg]
131 ± 10.9
127 ± 8.8
<0.001
131 ± 9.7
131 ± 8.6
0.438
24-h ambulatory DBP [mmHg]
81.5 ± 7.1
79.7 ± 7.0
0.013
81 ± 7.1
81 ± 7.5
0.976
Clinical (laboratory) central vascular parameters
Central SBP [mmHg]
123 ± 9.6
117 ± 10.4
<0.001
121 ± 9.9
121 ± 8.3
0.944
Central PP [mmHg]
44.4 ± 8.0
41.4 ± 6.6
0.004
43.5 ± 8.6
42.8 ± 7.5
0.471
Fonvard pressure pulse height [mmHg]
33 ± 5.7
30.2 ± 4.6
<0.001
32.5 ± 5.6
31.8 ± 4.5
0.216
Central office P\W [ms]
82 ± 1.6
8.0 ± 1.5
0.039
8.4 ± 1.3
8.3 ± 12
0.400
24-h ambulatory central vascular parameters
Central 24-h SBP [mmHg]
120.5 ± 9.3
117.3 ± 7.9
0.007
121 ± 9.1
121 ± 8.0
0.608
Central 24-h DBP [mmHg]
83.2 ± 7.3
81.1 ± 6.9
0.016
82.4 ± 7.1
82.4 ± 7.7
0.928
Central 24-h PWV [ms]
8.9 ± 1.3
8.8 ± 1.3
0.010
9.0 ± 1.4
90 ± 1.3
0.349
Changes in BP and vascular function after 12 weeks of treatment with E-L and M-I in comparison to baseline. Data are given as mean ± standard deviation. E, empagliflozin; L, linagliptm; M, metformin I, insulin glargine; SBP – systolic hood pressure; DBP, diastolic hood pressure; PP, pulse pressure; PWV, pulse wave velocity.
Conclusion: The combination of E+L significantly improves BP and vascular function in contrast to the combination of M+I. |
| first_indexed | 2024-04-13T07:08:06Z |
| format | Article |
| id | doaj.art-c7028f5ec6934546974e5fbceccf567a |
| institution | Directory Open Access Journal |
| issn | 1876-4401 |
| language | English |
| last_indexed | 2024-04-13T07:08:06Z |
| publishDate | 2020-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Artery Research |
| spelling | doaj.art-c7028f5ec6934546974e5fbceccf567a2022-12-22T02:56:57ZengBMCArtery Research1876-44012020-02-0125110.2991/artres.k.191224.0274.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 DiabetesChristian OttSusanne JungAgnes BoschDennis KannenkerilKristina StriepeRoland SchmiederBackground: Combination of insulin with oral antidiabetic drugs is a valid option, but oral combination therapy emerged as an alternative treatment in type 2 diabetes (T2DM). However, the effects on blood pressure (BP) and vascular function of such combination therapies is less clear. Methods: In this study 101 patients with T2DM were randomized to receive either empagliflozin 10 mg and linagliptin 5 mg (E+L group) orally or metformin and insulin glargine (M+I group, with dose adjustments according to glucose levels), for 3 months. Patients underwent BP and vascular examination at baseline and after 12 weeks of treatment, including measurement of office and ambulatory BP and vascular function under clinical and ambulatory conditions by validated systems. Results: In comparison to baseline, office, 24-hour ambulatory BP and central blood and pulse pressure (PP) values decreased significantly after 12 weeks of treatment with E+L, whereas there was no significant change in vascular parameters in the M+I group (Table 1). Comparing the 2 groups, there were significant decreases in 24-h ambulatory peripheral systolic (mean difference between the 2 groups: −5.2 ± 1.5 mmHg, p = 0.004), diastolic BP (−1.9 ± 1.0 mmHg, p = 0.036) and PP (−3.3 ± 1.0 mmHg, p = 0.007) in favour of E+L. Central systolic BP (−5.56 ± 1.9 mmHg, p = 0.009), forward pressure pulse height (−2.0 ± 0.9 mmHg, p = 0.028) and 24-h ambulatory central systolic (−3.6 ± 1.4 mmHg, p = 0.045), diastolic BP (−1.95 ± 1.1 mmHg, p = 0.041) and 24-h pulse wave velocity (−0.14 ± 0.05 m/s, p = 0.043) were reduced to a greater extent in the E+L group than in the M+I group. Table 1 E + L M + I Baseline 12 weeks p-value Baseline 12 weeks p-value Peripheral (brachial) BP values 24-h ambulatory SBP [mmHg] 131 ± 10.9 127 ± 8.8 <0.001 131 ± 9.7 131 ± 8.6 0.438 24-h ambulatory DBP [mmHg] 81.5 ± 7.1 79.7 ± 7.0 0.013 81 ± 7.1 81 ± 7.5 0.976 Clinical (laboratory) central vascular parameters Central SBP [mmHg] 123 ± 9.6 117 ± 10.4 <0.001 121 ± 9.9 121 ± 8.3 0.944 Central PP [mmHg] 44.4 ± 8.0 41.4 ± 6.6 0.004 43.5 ± 8.6 42.8 ± 7.5 0.471 Fonvard pressure pulse height [mmHg] 33 ± 5.7 30.2 ± 4.6 <0.001 32.5 ± 5.6 31.8 ± 4.5 0.216 Central office P\W [ms] 82 ± 1.6 8.0 ± 1.5 0.039 8.4 ± 1.3 8.3 ± 12 0.400 24-h ambulatory central vascular parameters Central 24-h SBP [mmHg] 120.5 ± 9.3 117.3 ± 7.9 0.007 121 ± 9.1 121 ± 8.0 0.608 Central 24-h DBP [mmHg] 83.2 ± 7.3 81.1 ± 6.9 0.016 82.4 ± 7.1 82.4 ± 7.7 0.928 Central 24-h PWV [ms] 8.9 ± 1.3 8.8 ± 1.3 0.010 9.0 ± 1.4 90 ± 1.3 0.349 Changes in BP and vascular function after 12 weeks of treatment with E-L and M-I in comparison to baseline. Data are given as mean ± standard deviation. E, empagliflozin; L, linagliptm; M, metformin I, insulin glargine; SBP – systolic hood pressure; DBP, diastolic hood pressure; PP, pulse pressure; PWV, pulse wave velocity. Conclusion: The combination of E+L significantly improves BP and vascular function in contrast to the combination of M+I.https://www.atlantis-press.com/article/125934393/view |
| spellingShingle | Christian Ott Susanne Jung Agnes Bosch Dennis Kannenkeril Kristina Striepe Roland Schmieder 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes Artery Research |
| title | 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes |
| title_full | 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes |
| title_fullStr | 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes |
| title_full_unstemmed | 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes |
| title_short | 4.6 Effects of Combined Therapy of Empagliflozin and Linagliptin Versus Metformin and Insulin Glargine on Blood Pressure and Vascular Function in Patients with Type 2 Diabetes |
| title_sort | 4 6 effects of combined therapy of empagliflozin and linagliptin versus metformin and insulin glargine on blood pressure and vascular function in patients with type 2 diabetes |
| url | https://www.atlantis-press.com/article/125934393/view |
| work_keys_str_mv | AT christianott 46effectsofcombinedtherapyofempagliflozinandlinagliptinversusmetforminandinsulinglargineonbloodpressureandvascularfunctioninpatientswithtype2diabetes AT susannejung 46effectsofcombinedtherapyofempagliflozinandlinagliptinversusmetforminandinsulinglargineonbloodpressureandvascularfunctioninpatientswithtype2diabetes AT agnesbosch 46effectsofcombinedtherapyofempagliflozinandlinagliptinversusmetforminandinsulinglargineonbloodpressureandvascularfunctioninpatientswithtype2diabetes AT denniskannenkeril 46effectsofcombinedtherapyofempagliflozinandlinagliptinversusmetforminandinsulinglargineonbloodpressureandvascularfunctioninpatientswithtype2diabetes AT kristinastriepe 46effectsofcombinedtherapyofempagliflozinandlinagliptinversusmetforminandinsulinglargineonbloodpressureandvascularfunctioninpatientswithtype2diabetes AT rolandschmieder 46effectsofcombinedtherapyofempagliflozinandlinagliptinversusmetforminandinsulinglargineonbloodpressureandvascularfunctioninpatientswithtype2diabetes |